omniture

China Health Holding Appoints Mr. Yu, XiaoFei as President

2007-02-13 13:30 1859

LAS VEGAS, Feb. 12 /Xinhua-PRNewswire-FirstCall/ -- China Health Holding, Inc.(OTC Bulletin Board: CHHH), a development stage pharmaceutical company with the goal of becoming a leading developer, manufacturer, marketer and

distributor of pharmaceutical products and dietary supplements in China and

worldwide, announced today that it has promoted Mr. Yu, XiaoFei as the

President of the Company.

Julianna Lu, the Founder and CEO of China Health Holding, noted that the

Company has successfully attracted and retained a group of world class

scientific, pharmaceutical and Traditional Chinese Medicine, or TCM, experts

and experienced business advisors to serve on the Company's management team

and board of directors.

As vice president and director, Mr. Yu helped develop 134 natural herbal

products within China Health Holding's two core product lines: King of Herbs

and Taoist Medicines based on the accomplishment of five thousand years of

Traditional Chinese Medicine. In 2004, Mr. Yu was elected to the board of

directors and was appointed vice president. He was previously the president

and director of Beijing's Taoist Tantric & Toltec Research & Development

Centre and is currently a research consultant at the Central TSM Research &

Development Institute. He is also a professor at the University of CCCP, where

he teaches Taoism, Taoist Medicine and Indian classical philosophy and

religion. Prior to teaching at the University of CCCP, from 1994 to 1999, Mr.

Yu was an associate professor in Taoism, Taoist Medicine, Buddhism and

Scientific Philosophy at Beijing University.

"Since 2004, XiaoFei Yu has served China Health Holding in many

capacities," said Julianna Yu, Founder and CEO of China Health Holding. "Mr.

Yu has been instrumental in helping the Company acquire an extensive range of

China SFDA drugs as well as China GMP accredited manufacturing plants. His

ability to opportunistically select and consolidate acquired businesses has

been essential to the success of our business model in this highly fragmented

industry."

Mr. Yu's comprehensive experience in Traditional Chinese Medicine will

continue to help China Health Holding build its vertically integrated business

model. In the next 12 to 24 months, the Company's main objective remains to

continue partnering with China SFDA certified drugs producers, China GMP

accredited manufacturing facilities, research and development centers and

Universities. Further pending acquisitions are expected to bring total assets

to US$100 million, gross revenue of approximately US$100 million and an annual

net income of US$10-15 million.

About China Health Holding

China Health Holding, Inc. is a development stage company with the goal of

becoming a leading developer, manufacturer, marketer and distributor of

pharmaceutical products and dietary supplements in China and worldwide. It has

extensive expertise in the field of traditional Chinese medicine and the

Chinese pharmaceutical industry. Its immediate goal is the profitable

penetration of the growing global and China pharmaceutical industry and market

through acquisitions of major pharmaceutical companies in the People's

Republic of China and worldwide. Its long-term plans include the development

of a pharmaceutical drug pipeline and technology based on its knowledge of

traditional Chinese medicine and the pharmaceutical industry in the People's

Republic of China.

The company has two wholly-owned subsidiaries: (i) China Health World

Pharmaceutical Corporation, which will develop, manufacture and commercialize

natural medications for diseases and conditions related to diabetes,

cardiovascular disease and neurological disorders; and (ii) China Health World

Trade Corporation, which will develop China Health's retail/franchise

infrastructure along with worldwide branding, multimedia marketing and multi-

channel distribution to global customers and markets.

China Health owns the exclusive worldwide rights to a total of 134

proprietary natural herbal medicinal products/formulas in two natural herbal

medicinal product lines: King of Herbs and Taoist Medicinal. Please visit

http://www.chinahealthholding.com for the Company's profile.

For investor and media inquiries, please contact:

China Health Holding, Inc.

Mr. Yu, XiaoFei

President

Tel: 1-604-608-6788 and Tel: 1-877-883-0979

Tel: 86-10-1370-133-1287 (Beijing China)(Text Message)

Email: info@chinahealthholding.com

http://www.chinahealthholding.com

In the United States, and North America

Investor Relations International (Los Angeles)

Haris Tajyar, Managing Partner

Tel: 1-818-382-9702

In China, Hong Kong and Asia, Rest of World

Rory Macpherson

Consultant

Ogilvy Public Relations Worldwide

Office: 86-10-8520-6553

Safe Harbor Statement: To the extent that statements in the press release

are not strictly historical, including statements as to revenue projections,

business strategy, outlook, objectives, future milestones, plans, intentions,

goals, future financial conditions, future collaboration agreements, the

success of the Company's development, events conditioned on stockholder or

other approval, or otherwise as to future events, such statements are forward

looking, all forward-looking statements, whether written or oral, and whether

made by or on behalf of the Company, are expressly qualified by the cautionary

statements and any other cautionary statements, which may accompany the

forward-looking statements, and are made pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995. The

forward-looking statements contained in this release are subject to certain

risks and uncertainties that could cause actual results to differ materially

from the statements made. Other important factors that could cause actual

results to differ materially include the following: business conditions and

the amount of growth in the Company's industry and general economy;

competitive factors; ability to attract and retain personnel; the price of the

Company's stock; and the risk factors set forth from time to time in the

Company's SEC reports, including but not limited to its annual report on Form

10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. In

addition, the company disclaims any obligation to update or correct any

forward-looking statements in all of the Company's press releases to reflect

events or circumstances after the date hereof.

Source: China Health Holding, Inc.
Related Stocks:
OTC:CHHL
collection